[Effect of veralipride on LH, FSH, and PRL levels and on the climacteric syndrome].
21 women with menopausal disorders were given veralipride, which is a benzamide derivative having a central anti-dopaminergic action. The LH, FSH and PRL plasma levels were controlled before and after treatment. Treatment, using veralipride at a daily dose of 100 mg for 20 days, improved the climacteric syndrome, and, in particular, the sudden hot flushes. The FSH plasma levels remained unchanged, the LH levels were reduced, although they remained high, and the PRL levels increased during the course of the treatment.
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D005260:Female; D005483:Flushing / Q000628:therapy; D005640:Follicle Stimulating Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000494:pharmacology
D006065:Gonadotropins, Pituitary; D013469:Sulpiride; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C027429:veralipride
Effet du véralipride sur les taux de LH, FSH et PRL et sur le syndrome climatérique.